China SXT Pharmaceuticals annual capital expenditures (capex)
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
China SXT Pharmaceuticals Capital Expenditures (CapEx) Growth & History (SXTC)
China SXT Pharmaceuticals's capital expenditures (capex) was $1.3M for fiscal 2026.
View full China SXT Pharmaceuticals company overviewChina SXT Pharmaceuticals annual capital expenditures (capex) history
| Fiscal year | Period ended | Capital expenditures (CapEx) | Change | Growth |
|---|---|---|---|---|
| 2026 | 2026-03-31 | $1.3M | $1.2M | +61734.95% |
| 2025 | 2025-03-31 | $2,023 | −$5,040 | −71.36% |
| 2024 | 2024-03-31 | $7,063 | −$63,621 | −90.01% |
| 2023 | 2023-03-31 | $70,684 | $9,752 | +16.00% |
| 2022 | 2022-03-31 | $60,932 | −$17,370 | −22.18% |
| 2021 | 2021-03-31 | $78,302 | −$52,537 | −40.15% |
| 2020 | 2020-03-31 | $130,839 | −$404,986 | −75.58% |
| 2019 | 2019-03-31 | $535,825 | $99,808 | +22.89% |
| 2018 | 2018-03-31 | $436,017 | $256,841 | +143.35% |
| 2017 | 2017-03-31 | $179,176 | — | — |
China SXT Pharmaceuticals capital expenditures (capex) trends
Over the last five fiscal years, China SXT Pharmaceuticals's capital expenditures (capex) increased from $78,302 to $1.3M, a change of $1.2M.
About the metric
What capital expenditures (CapEx) mean
Capital expenditures, commonly called CapEx, are cash investments in long-lived assets such as property, plants, equipment, infrastructure, and productive software. CapEx can support future growth or maintain existing operations, but it reduces current-period free cash flow.
Calculation and source
SEC-reported capital expenditures
TickerStat standardizes cash payments for property, plant, equipment, and other productive assets reported in company SEC filings. When a filer reports separate qualifying CapEx components instead of a total, those components are combined for the same fiscal period. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review China SXT Pharmaceuticals source filings ↗